Ultrastaging of Early Colon Cancer
OBJECTIVES:
- Determine whether the immunohistochemical and molecular presence of micrometastases in
≥ 12 lymph nodes removed during en-bloc resection in patients with stage II colon
cancer correlates with 3-year disease-free survival.
- Evaluate the prognostic significance of molecular markers detected in the primary tumor
and develop a microarray-based gene signature for stage II colon cancer.
OUTLINE: This is a multicenter study.
Tumor tissue and regional lymph node samples are collected during surgery for analysis of
micrometastases and molecular markers by immunohistochemistry, qRT-PCR, MM qRT-PCR,
qRDNA-PCR, and microarray profiling.
Patients are followed up periodically for 4 years after surgery.
Interventional
Primary Purpose: Diagnostic
Disease-free survival (time to local or distant recurrence after resection)
No
Anton J. Bilchik, MD, PhD, FACS
Principal Investigator
Jonsson Comprehensive Cancer Center
Unspecified
CDR0000649763
NCT00949312
May 2009
Name | Location |
---|---|
Walter Reed Army Medical Center | Washington, District of Columbia 20307-5000 |
Jonsson Comprehensive Cancer Center at UCLA | Los Angeles, California 90095-1781 |